Cabaletta Bio (NASDAQ:CABA) Given New $13.00 Price Target at Morgan Stanley

Cabaletta Bio (NASDAQ:CABA) had its price objective cut by Morgan Stanley from $14.00 to $13.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cabaletta Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Cabaletta Bio Price Performance

Shares of CABA stock opened at $2.67 on Tuesday. The stock has a market cap of $257.01 million, a P/E ratio of -1.17 and a beta of 3.25. The company has a fifty day moving average price of $2.87 and a two-hundred day moving average price of $2.55. Cabaletta Bio has a one year low of $0.99 and a one year high of $3.78.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. As a group, equities research analysts anticipate that Cabaletta Bio will post -2.34 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Steve Gavel acquired 22,170 shares of Cabaletta Bio stock in a transaction on Wednesday, January 21st. The stock was purchased at an average cost of $2.27 per share, with a total value of $50,325.90. Following the completion of the transaction, the insider directly owned 22,170 shares in the company, valued at $50,325.90. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Simon acquired 11,061 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was bought at an average price of $2.28 per share, for a total transaction of $25,219.08. Following the completion of the acquisition, the director owned 147,205 shares of the company’s stock, valued at approximately $335,627.40. The trade was a 8.12% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 127,668 shares of company stock worth $286,211 in the last quarter. Insiders own 11.25% of the company’s stock.

Institutional Trading of Cabaletta Bio

Several hedge funds and other institutional investors have recently modified their holdings of the stock. CRA Financial Services LLC grew its stake in Cabaletta Bio by 36.4% in the 3rd quarter. CRA Financial Services LLC now owns 15,000 shares of the company’s stock valued at $35,000 after buying an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Cabaletta Bio during the fourth quarter worth approximately $34,000. ANTIPODES PARTNERS Ltd acquired a new stake in Cabaletta Bio during the fourth quarter worth approximately $38,000. Clear Harbor Asset Management LLC bought a new stake in shares of Cabaletta Bio during the fourth quarter worth approximately $43,000. Finally, Jones Financial Companies Lllp bought a new stake in shares of Cabaletta Bio during the third quarter worth approximately $47,000.

Cabaletta Bio News Roundup

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: Company update says the rese-cel myositis BLA submission remains on track for 2027 based on a 17‑patient single‑arm registrational cohort and includes an outpatient dosing option — a clearer regulator timeline and an outpatient pathway can materially de‑risk and increase the program’s commercial potential. Read More.
• Positive Sentiment: Q4/FY2025 results: EPS of ($0.40) beat consensus ($0.45) — a modest beat that may ease near‑term execution concerns and reduce financing/valuation pressure. Read More.
• Positive Sentiment: Guggenheim raised its price target from $15 to $16 and initiated/maintained a “Buy” view, signaling strong upside vs. the current price and likely supporting positive sentiment among growth investors. Read More.
• Neutral Sentiment: An analyst roundup (TipRanks/Globe and Mail) discussed CABA among other healthcare names — useful for context but not a direct catalyst. Read More.
• Negative Sentiment: Morgan Stanley lowered its price target from $14 to $13 but kept an “Overweight” rating — the cut in target is a mild negative for near‑term sentiment despite the positive rating stance. Read More.
• Negative Sentiment: Multiple short‑interest alerts say there was a “large increase” in March, but the underlying reported figures are inconsistent (showing 0 shares/NaN changes and 0.0 days‑to‑cover). The headlines alone can spark selling or volatility even though the data appears erroneous — investors should treat these short‑interest claims with caution and await reliable filings. (Multiple market feeds)

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.